Abbott Laboratories (SWX:ABT)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 191.22B |
| Revenue (ttm) | 37.43B |
| Net Income (ttm) | 11.89B |
| Shares Out | n/a |
| EPS (ttm) | 6.81 |
| PE Ratio | 16.08 |
| Forward PE | 25.14 |
| Dividend | 1.99 (2.13%) |
| Ex-Dividend Date | Apr 15, 2025 |
| Volume | 20 |
| Average Volume | n/a |
| Open | 92.00 |
| Previous Close | 93.50 |
| Day's Range | 92.00 - 93.50 |
| 52-Week Range | 89.00 - 96.00 |
| Beta | 0.68 |
| RSI | 31.18 |
| Earnings Date | Jul 16, 2025 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2024, Abbott Laboratories's revenue was $41.95 billion, an increase of 4.59% compared to the previous year's $40.11 billion. Earnings were $13.35 billion, an increase of 134.19%.
Financial numbers in USD Financial StatementsNews
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Sainte Nutritional Files For Hong Kong IPO
The Qingdao-based maker of food for special medical purposes is challenging international firms that still dominate the China market but could face tariff uncertainties Key Takeaways: Sainte Nutrition...
Faulty prostate cancer tests leave 406 Hong Kong patients with nervy wait
Hong Kong public hospitals are reviewing blood test results of more than 400 patients after batches of a reagent were found to have quality issues that could produce false positives for prostate cance...
Best Dividend Aristocrats For June 2025
Dividend Aristocrats have slightly outperformed the S&P 500 year-to-date, despite underperforming in April and May. Dividend growth remains robust, with 41 of 69 Aristocrats announcing increases in 20...
Abbott Receives FDA Approval for Tendyne™, First-of-Its-Kind Device to Replace the Mitral Valve Without Open-Heart Surgery
The Tendyne system replaces mitral valves that are not functioning properly due to a buildup of calcium in the base of the valves, known as severe mitral annular calcification (MAC) Tendyne offers a n...
Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story
Senseonics Holdings, Inc. Announces Closing of Public Offering, Including Exercise in Full of the Underwriters' Option to Purchase Additional Shares, and Closing of Private Placement
Public offering results in gross proceeds of $57.5 million Private placement results in gross proceeds of approximately $20.3 million GERMANTOWN, Md., May 21, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdi...
Abbott India's quarterly profit climbs 28% on strong demand
Drugmaker Abbott India reported a 28% rise in fourth-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications.
Abbott's Libre® Technology is First Continuous Glucose Monitor Associated with Reduced Hospitalizations for Heart Complications in People with Diabetes
New data reveal a 78% reduction in cardiovascular disease-related hospitalizations for people living with Type 1 diabetes with prior severe low blood sugar episodes.1 This significant decrease is link...
Recent Filing Shows That Rep. Bruce Westerman Sold Over $137K Worth of Apple Stock
An official report on May 12, 2025 reveals Representative Bruce Westerman's recent sale of Apple (NASDAQ: AAPL) stock, valued between $137,095 and $1,530,000. The transaction took place on May 12, 20...
Abbott Labs CEO on federal health care spending, investing in healthy people and weight loss drugs
Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.
Abbott Labs CEO on federal health care spending, investing in healthy people and weight loss drugs
Robert Ford, Abbott Labs CEO, joins 'Power Lunch' to discuss government spending on health care and technological investments.
Jensen Huang, Magic Johnson, Patrick Dempsey, Linda Yaccarino And More Bigwigs Headline Milken Global Conference 2025: What You Need To Know
The Milken Institute's 28th annual Global Conference began on Sunday and will run through May 7 at the Beverly Hilton in Los Angeles. What Happened: Held under the theme “Toward a Flourishing Future,”...
US judge allows testimony that Abbott and Mead Johnson preterm baby formula caused deadly disease
A federal judge on Friday said she will allow expert testimony that formula made by Abbott Laboratories and Reckitt Benckiser subsidiary Mead Johnson for premature babies can cause a fatal intestinal ...
MotoAmerica Becomes First Sports Organization to Use Abbott's Rapid Blood Test for Concussion Evaluation On-site at Races
The test, run on Abbott's portable i-STAT ® Alinity® hand-held instrument, uses whole blood to help evaluate patients 18 years of age and older with a suspected mild traumatic brain injury, or concuss...
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Best Dividend Aristocrats For May 2025
Despite a strong start, the Dividend Aristocrats are underperforming the S&P 500 in April, with NOBL down 4.88% and SPY down 1.53%. The best-performing Dividend Aristocrats YTD include Consolidated Ed...
Abbott Integrates Libre's Data with Epic's Electronic Health Record System, Providing Healthcare Professionals Seamless Glucose Monitoring Information
Collaboration brings together FreeStyle Libre® Systems, the world's leading continuous glucose monitoring technology (CGM)1 with Epic, a healthcare software company, to streamline access to CGM data f...
A Look Into Abbott Laboratories Inc's Price Over Earnings
In the current market session, Abbott Laboratories Inc. (NYSE: ABT) share price is at $129.36, after a 0.40% spike. Moreover, over the past month, the stock fell by 1.77% , but in the past year, incr...
Abbott Laboratories Unveils Promising Data on AVEIR Leadless Pacemaker | ABT stock news
Abbott Laboratories Unveils Promising Data on AVEIR Leadless Pacemaker | ABT stock news
Abbott Highlights New AVEIR™ Data, Initiates Trial for the Company's Conduction System Pacing Technology
Late-breaking data from Abbott's groundbreaking first-in-human study demonstrated successful implantation of the company's AVEIR Conduction System Pacing (CSP) leadless pacemaker Enrollment has also b...
New Clinical Study Data Showcase Long-Term, Sustained Benefits of Abbott's Volt™ PFA System for Patients with AFib
Long-term data from the Volt CE Mark Study show strong results out to 12 months in patients receiving pulsed field ablation (PFA) therapy with the Volt™ PFA System The 12-month results of the Volt CE ...
2025 Dividend Kings: Weathering Tariff Volatility Better Than The Market
The Dividend Kings are outperforming the S&P 500 in 2025 by 8.94%. Top performers include National Fuel & Gas (+28.88%), Consolidated Edison (+28.10%), and Middlesex Water Company (+21.00%). Promising...
Abbott Labs' Rally Is Well Deserved - Fade The Rally For Now
Abbott's growth potential with GLP-1 tailwinds, robust FCF, and dividend growth. Read more on how ABT navigates tariffs while staying poised to outperform.
Abbott Labs is a textbook recession play, says Jim Cramer
'Mad Money' host Jim Cramer checks in on Abbott Labs.